Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions

[1]  S. Loft,et al.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2. , 1993, Biochemical pharmacology.

[2]  M. Romkes,et al.  Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. [Erratum to document cited in CA114(15):137136r] , 1993 .

[3]  Kenneth J. Fishman,et al.  Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity , 1992, Clinical pharmacology and therapeutics.

[4]  A. Avenoso,et al.  Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients , 1992, Therapeutic drug monitoring.

[5]  D. Koop.  Oxidative and reductive metabolism by cytochrome P450 2E1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  B. Tang,et al.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities , 1991, Clinical pharmacology and therapeutics.

[7]  A. Sperber.  Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy , 1991, Drug safety.

[8]  A. Breckenridge,et al.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. , 1991, British journal of clinical pharmacology.

[9]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.

[10]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[11]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[12]  K. Brøsen.  Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics , 1990, Clinical pharmacokinetics.

[13]  M. Butler,et al.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. Bell,et al.  Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. , 1988, Journal of clinical psychopharmacology.

[15]  R. Edwards,et al.  A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. , 1988, British journal of clinical pharmacology.

[16]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[17]  S. Otton,et al.  Sparteine oxidation polymorphism in Denmark. , 2009, Acta pharmacologica et toxicologica.

[18]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[19]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[20]  L. Gram,et al.  Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man , 1972, British medical journal.